Since MLCK is the limiting enzyme of activation with redistribution of cytoskeleton morphologically, anti-MLCK agents might be a potential candidate for treatment of inflammatory diseases, including atherosclerosis, pancreatitis and IBD 40. Here, MYLK is linked to inflammatory bowel disease.